Shattuck (STTK) Announces Positive Interim Data on Cancer Drug [Yahoo! Finance]
Shattuck Labs, Inc. (STTK)
Company Research
Source: Yahoo! Finance
azacitidine, in frontline higher-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant (TP53m) acute myeloid leukemia (AML) patients. SL-172154 is an investigational agonist redirected checkpoint fusion protein, designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction and activate the CD40 costimulatory receptor to bolster an anti-tumor immune response in patients with advanced cancer. The latest data show that the rate of complete remission (CR) has improved since the last data release in December. These data are to be featured in a poster presentation during the European Hematology Association 2024 Congress. In the HR MDS cohort, as of the data cut-off date of Apr 23, 2024, 21 out of the 24 patients treated had TP53m, 16 had complex karyotype and seven had therapy-related MDS. The objective response rate (ORR) was 67%. Ten patients achieved a CR with 3.6 months as the median time to CR, and nine are undergoing treatment. Three patients proceeded to allogeneic
Show less
Read more
Impact Snapshot
Event Time:
STTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STTK alerts
High impacting Shattuck Labs, Inc. news events
Weekly update
A roundup of the hottest topics
STTK
News
- Shattuck Labs, Inc. (NASDAQ: STTK) had its price target lowered by analysts at HC Wainwright from $28.00 to $16.00. They now have a "buy" rating on the stock.MarketBeat
- Hold For Now: Shattuck Labs' SL-172154 Potential In Early Trials [Seeking Alpha]Seeking Alpha
- Shattuck Labs, Inc. (NASDAQ: STTK) had its price target lowered by analysts at Citigroup Inc. from $10.00 to $9.00. They now have a "buy" rating on the stock.MarketBeat
- Shattuck Labs, Inc. (NASDAQ: STTK) was downgraded by analysts at BTIG Research from a "buy" rating to a "neutral" rating.MarketBeat
- Shattuck Labs, Inc. (NASDAQ: STTK) had its price target lowered by analysts at Needham & Company LLC from $12.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
STTK
Earnings
- 2/29/24 - Beat
STTK
Sec Filings
- 6/21/24 - Form 4
- 6/21/24 - Form 4
- 6/21/24 - Form 4
- STTK's page on the SEC website